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Abstract: Severe obesity is a disease associated with multiple adverse effects on health. Metabolic 
bariatric surgery (MBS) can have significant effects on multiple body systems and was shown to 
improve inflammatory markers in previous short-term follow-up studies. We evaluated associa-
tions between changes in inflammatory markers (CRP, IL6 and TNFα) and circulating proteins after 
MBS. Methods: Sequential window acquisition of all theoretical mass spectra (SWATH-MS) prote-
omics was performed on plasma samples taken at baseline (pre-surgery) and 6 and 12 months after 
MBS, and concurrent analyses of inflammatory/metabolic parameters were carried out. The change 
in absolute abundances of those proteins, showing significant change at both 6 and 12 months, was 
tested for correlation with the absolute and percentage (%) change in inflammatory markers. Re-
sults: We found the following results: at 6 months, there was a correlation between %change in IL-
6 and fold change in HSPA4 (rho = −0.659; p = 0.038) and in SERPINF1 (rho = 0.714, p = 0.020); at 12 
months, there was a positive correlation between %change in IL-6 and fold change in the following 
proteins—LGALS3BP (rho = 0.700, p = 0.036), HSP90B1 (rho = 0.667; p = 0.05) and ACE (rho = 0.667, 
p = 0.05). We found significant inverse correlations at 12 months between %change in TNFα and the 
following proteins: EPHX2 and ACE (for both rho = −0.783, p = 0.013). We also found significant 
inverse correlations between %change in CRP at 12 months and SHBG (rho = −0.759, p = 0.029), 
L1CAM (rho = −0.904, p = 0.002) and AMBP (rho = −0.684, p = 0.042). Conclusion: Using SWATH-MS, 
we identified several proteins that are involved in the inflammatory response whose levels change 
in patients who achieve remission of T2DM after bariatric surgery in tandem with changes in IL6, 
TNFα and/or CRP. Future studies are needed to clarify the underlying mechanisms in how MBS 
decreases low-grade inflammation. 
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Obesity is recognized as the fastest growing problem affecting public health world-
wide and has many consequences [1–3]. Obesity often has multiple predisposing and pre-
cipitating factors and is itself associated with a high mortality rate and with comorbid 
conditions such as type 2 diabetes mellitus (T2DM), metabolic syndrome, hypertension, 
dyslipidaemia, several cancers [4], premature cell ageing [5], sleep apnoea and osteoar-
thritis [6,7]. T2DM is strongly associated with increasing BMI; however, its aetiology re-
mains multifactorial and not completely characterized. Inflammation has been considered 
an integral part to the development of T2DM in both promoting insulin resistance and 
beta cell dysfunction [8]. The obese phenotype results in a chronic low-grade inflamma-
tory state characterized by the putative secretion of pro-inflammatory markers by adipo-
cytes [8], including those that may contribute to the inflammatory component in the de-
velopment of T2DM (IL6, TNFα and IL1β) [9–11] by hypertrophic adipocytes. 
Metabolic bariatric surgery (MBS) results in metabolic pathway recalibration, which 
phenotypically can manifest as early remission of T2DM in the days following surgery 
before any appreciable weight loss has occurred [12]. Additionally, MBS has been shown 
not only to be an effective therapy for weight loss, but also to improve a variety of meta-
bolic parameters conferring protection from cardiovascular disease (CVD) and other dis-
orders [13,14]. Immediate post-operative weight-independent hormonal changes com-
bined with ensuing weight loss can result in remission of T2DM in up to 80% of patients 
after one year [14]. MBS results in major metabolic changes and there remain many ques-
tions as to the metabolic and inflammatory pathways that are changed following MBS, 
with significant consequences for health outcomes and how biological phenotype pre-
MBS may relate to outcomes post-MBS. 
In relation to this, the study of proteins and their function helps investigators to de-
cipher the cellular mechanisms that associate with change in phenotype in relation to spe-
cific interventions [15,16]. When major metabolic change occurs, blood protein compo-
nents have a key role and can be altered significantly. We have recently shown significant 
changes in the proteome for eight proteins at 6 and 12 months post-BS, and several of 
these are key components in metabolic and inflammatory pathways [17]. We now set out 
to identify potential proteins related to inflammatory markers (IL6, TNFα and C-reactive 
protein—CRP) in plasma samples of people achieving remission of T2DM following MBS. 
2. Materials and Methods 
Longitudinal plasma samples from 10 individuals who achieved remission of T2DM 
following gastric bypass (n = 7) or sleeve gastrectomy (n = 3) were analysed. Sequential 
window acquisition of all theoretical mass spectra (SWATH-MS) proteomics [18] was per-
formed on plasma samples taken at 4 months before (baseline) and 6 and 12 months after 
MBS, and concurrent analyses of a panel of inflammatory/metabolic parameters were car-
ried out. 
All patients were of White ethnicity. Remission was defined as reduction of glycosyl-
ated haemoglobin (HbA1c) below 42 mmol/mol with cessation of all antidiabetic therapy 
at 12 months [19]. SWATH-MS proteomics was carried out on 29 plasma samples with the 
following sample subgroups: baseline samples, pre-bariatric surgery samples (taken at 4 
months prior to MBS (n = 10); post-bariatric surgery samples, 6 months follow up (n = 10); 
and post-bariatric surgery samples, 12 months follow up (n = 9). 
Details of the SWATH-MS analysis are described in our previous publication [17]. 
Percentage changes were calculated for each of these parameters at 6 and 12 months 
compared to baseline. 
2.1. Identification of Proteins 
SWATH-MS characterised a total of 467 proteins that changed after bariatric surgery 
using analysis performed in R and the bioconductor (release 3.5) packages SWATH2Stats 
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(Bioconductor, https://www.bioconductor.org) and MSstats (Bioconductor, 
https://www.bioconductor.org). We identified 38 proteins with significant fold changes 
between baseline and 6 months, and 25 proteins with significant fold changes between 
baseline and 12 months [17]. The detailed methods for SWATH-MS analysis were de-
scribed previously [17]. In summary, plasma samples (10 µL) were immunodepleted and 
concentrated afterwards using protein-depletion spin columns and Amicon filters, respec-
tively. Each sample was reduced, alkylated and digested prior to lyophilisation. Samples 
were then analysed by SWATH-MS with a microflow LC-MS system comprising an Eksi-
gent nanoLC 400 autosampler and an Eksigent nanoLC 425 pump coupled to a SCIEX 
6600 Triple-TOF (SCIEX, Framingham, MA, USA) mass spectrometer with a DuoSpray 
ion source. 
We constructed correlation matrices between percentage changes in inflammatory 
markers (CRP, IL6 and TNFα) and fold changes in significant proteins identified by 
SWATH-MS at each time point of 6 and 12 months, as described above. 
2.2. Determination of Glycosylated Haemoglobin (HbA1c), Glucose, Insulin and Inflammatory 
Markers 
HbA1c was measured on an Hb9210 Premier autoanalyser (boranate affinity and 
high-performance liquid chromatography (Menarini Diagnostics, Wokingham, UK)). 
Glucose and insulin were measured using Abcam ELISA kits (Abcam, Cambridge, UK), 
and the HOMA2 calculator (https://www.dtu.ox.ac.uk/homacalculator/) was used to cal-
culate the homeostatic model assessment of insulin resistance (HOMA-IR) and beta cell 
function (HOMA-B) [20]. 
The inflammatory markers (interleukin6 (IL6), tumour necrosis factor-alpha (TNFα) 
and C-reactive protein (CRP) were measured using ELISA kits (Human IL-6, TNFα or 
CRP Quantikine HS ELISA Kit, R&D Systems, Minneapolis, MI, USA) according to the 
manufacturer’s instructions. 
2.3. Ethics 
Informed consent was obtained from each participant before recruitment. This re-
search adhered to the tenets of the Declaration of Helsinki. All participants provided writ-
ten informed consent. The study was approved by the Greater Manchester Research Eth-
ics Committee (REC No:11/NW/0731, IRAS ID: 85208). 
2.4. Statistical Analysis 
Statistical analysis was carried out on SPSS for Mac (Version 23.0, IBM Corporation, 
New York, NY, USA). Normality was determined by using the Shapiro–Wilk test and by 
visualising the histogram and normal Q–Q plot. To assess within- and between-group 
differences, we used one-way analysis of variance for parametric variables and Fried-
man’s test for non-parametric variables. A significant p value was considered to be <0.05 
(post hoc Tukey). 
We tested for correlations of those plasma proteins with significant fold change dif-
ference at each time point (6 and 12 months after MBS) and percentage (%) change in 
inflammatory markers (IL6, TNFα and CRP). Correlational analysis was done using 
Spearman’s rank correlation coefficient as all variables were non-parametrically distrib-
uted. 
3. Results 
Anthropometric and clinical results are displayed in Table 1. BMI (p < 0.001) and 
HbA1c (p < 0.001) declined significantly at both 6 and 12 months. IL6 decreased signifi-
cantly only at 12 months (t = 2.585, p = 0.029), and there were no differences observed 
between baseline vs. 6 months (p = 0.160). CRP, TNF-α, HOMA-IR and HOMA-B declined 
numerically but did not show statistical significance at any time points. 
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Table 1. Anthropometric and clinical results from (n = 10) individuals having undergone metabolic bariatric surgery (MBS) 
at baseline and 6 and 12 months after MBS. 
 
Baseline 
(mean ± SEM) 
6 Months 
Post-MBS 
(mean ± SEM) 
12 Months 
Post-MBS 
(mean ± SEM) 
p Value (Baseline x 6 
Months) 
p Value (Baseline x 12 
Months) 
BMI 54.9 ± 3.26 41.8 ± 2.20 38.6 ± 1.60 <0.0001 * <0.0001 * 
HbA1c 56.0 ± 4.46 40.0 ± 1.70 36.44 ± 1.01 0.002 * 0.004 * 
IL6 6.29 ± 1.19 4.8 ± 0.96 4.57 ± 1.10 0.160 0.029 * 
TNFα 5.98 ± 0.70 5.27 ± 1.20 4.59 ± 0.67 0.689 0.245 
CRP 9.07 ± 2.45 7.14 ± 1.71 5.11 ± 1.88 0.226 0.180 
HOMA-IR 0.56 ± 0.17 0.48 ± 0.19 0.36 ± 0.08 0.741 0.380 
HOMA-B 331.86 ± 83.69 413.85 ± 104.60 376.43 ± 72.88 0.443 0.734 
Results were calculated by a paired T test and considered significant when* p values ≤ 0.05. 
The list of proteins that correlated with inflammatory markers in relation to fold 
change at specific time points are shown on Table 2. In particular, L1 cell adhesion mole-
cule (L1CAM) and sex hormone-binding globulin (SHBG) levels increased while heat 
shock protein 90 Beta family member 1 (HSP90B1) and heat shock protein 4 (HSPA4) lev-
els fell. 
Table 2. Fold change in relevant proteins that showed correlations with inflammatory markers at 6 or 12 months post-
surgery. 
Protein (Gene Symbol) 
Fold Change ± SEM at 6 
Months 
Fold Change ± SEM at 12 
Months 
Heat shock protein 4 (HSPA4) 0.7648 ± 0.10156 N/S 
Serpin family F member 1 (SERPINF1) 0.7906 ± 0.06724 N/S 
Galectin 3 binding protein (LGALS3BP) N/S 0.7074 ± 0.08600 
Heat shock protein 90 Beta family member 1 (HSP90B1) N/S 0.7858 ± 0.07666 
Angiotensin-converting enzyme (ACE) N/S 0.7888 ± 0.07232 
Epoxide hydrolase 2 (EPHX2) N/S 0.7587 ± 0.07564 
Sex hormone-binding globulin (SHBG) N/S 6.1816 ± 1.83129 
L1 cell adhesion molecule (L1CAM) N/S 1.6862 ± 0.22992 
Alpha-1-microglobulin/Bikunin precursor (AMBP) N/S 1.3137 ± 0.11014 * 
N/S non-significant. * p ≤ 0.05 
3.1. Changes in Inflammatory Markers vs. the Proteome 
We found significant correlations between the %change in IL-6 and fold change in 
several proteins of relevance to inflammation. 
At 6 months: there was a correlation between %change in IL-6 and fold change in 
HSPA4 (rho = −0.659; p = 0.038) and in SERPINF1: rho = 0.714, p = 0.020 (Figure 1). 




Figure 1. Spearman’s correlations between IL6 % change and plasma proteins at 6 months post-bariatric surgery. 
At 12 months: there was a positive correlation between % change in IL-6 and the fold 
change in the following proteins—LGALS3BP: rho = 0.700, p = 0.036; HSP90B1: rho = 0.667, 









Figure 2. Spearman’s correlations between IL6 (A), TNFα (B) and CRP (C) and plasma proteins at 12 months post-bariatric 
surgery. 
In relation to TNFα, we found significant correlations only at 12 months. These were 
inverse correlations between %change in TNFα and the following proteins—EPHX2 and 
ACE—for both rho = −0.783, p = 0.013 (Figure 2B). 
We also found significant inverse correlations between %change in CRP at 12 months 
and SHBG (rho = −0.759, p = 0.029), L1CAM (rho = −0.904, p = 0.002) and AMBP (rho = 
−0.684, p = 0.042) (Figure 2C). 
4. Discussion 
In this study, we identified key proteins that change after bariatric surgery in associ-
ation with changes in traditional inflammatory markers (IL6, CRP and TNFα) in 10 pa-
tients who experienced remission of T2DM. IL6 declined significantly at 12 months com-
pared to baseline. We did not find a statistically significant decline in CRP or TNFα. How-
ever, we attribute this to the relatively low number of samples, as previous studies have 
confirmed that these markers consistently reduce after metabolic bariatric surgery [21], 
and for this reason, we opted to include these markers in our correlation analysis. 
Bariatric surgery brings multiple benefits for severe obesity. The reduction of weigh 
relates to reduction of comorbidities, such as cardiovascular disease, T2DM, dyslipidae-
mia, hypertension and low-grade inflammation [13,14]. Subjects undergoing MBS show 
reduction in various inflammatory indicators, such as CRP and IL6, accompanied by im-
provements in insulin sensitivity and cardiovascular risk [14]; however, these findings are 
not always consistent, due to the variability of procedures. 
The percentage decline at 6 months after surgery in IL6 correlated with the fold 
change in HSPA4 and with SERPINF1. HSPA4 functions as a cytosolic chaperone involved 
in facilitating protein folding, degradation, complex assembly and translocation. HSPA4 
appears to be induced by states of chronic inflammation [22]. Previous work has shown 
elevation of HSPA4 to occur in tandem with length of time since diagnosis in type 2 dia-
betes mellitus (T2DM) [23]. HSPA4 has also been associated with inhibition of nitric oxide 
production correlating with CRP levels in individuals with T2DM [19]. Styger et al. 
demonstrated reduction in both serum and liver HSPA4 in a murine model after MBS [24]. 
Our work demonstrates a significant reduction in HSPA4, which correlated with percent-
age change in IL6 between baseline and 6 months; however, this correlation was not main-
tained at 12 months. Further work is required to determine the role of this protein in the 
pathophysiology of T2DM. 
SERPINF1 is a neurotrophic protein among the most abundant glycoproteins se-
creted by adipocytes [25] and its genetic variants have been previously associated with 
obesity, insulin resistance, overall adiposity and circulating leptin levels [26]. Previous 
proteomic work has demonstrated a decline in this protein in association with inflamma-
tory markers [27]. Administration of SERPIN1F has been shown to have anti-inflamma-
tory effects in the progression of diabetic nephropathy and amelioration of albuminuria 
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in a murine streptozocin-induced diabetic model [28]. Our results show a decline in SER-
PIN1F in association with a decline in IL6, suggesting that SERPIN1F may be marker of 
inflammatory resolution in our bariatric cohort. 
The decrease seen at 12 months post-MBS vs. baseline in IL6 was correlated positively 
with fold changes in LGALS3BP, HSP90B1 and ACE. LGALS3BP is a secreted protein that 
interacts with its ligand to promote cell–cell adhesion that can initiate pathologic and pro-
inflammatory signals [29,30]. A number of studies have noted its role in cancer pathogen-
esis, and its role as cancer biomarker has been suggested [31–33]. Melin et al. noticed that 
higher levels of this protein were associated with elevated total cholesterol and lower 
HDL, especially in women [34]. Chen et al. also found that elevation of LGALS3BP was an 
independent risk factor for impaired insulin insensitivity [35]. In a prospective cohort 
study of 2922 individuals, LGALS3BP was found to be independently associated with all-
cause and cardiovascular mortality [35]. The authors also found significant associations 
with other markers of metabolic distress and inflammation. Our study demonstrated a 
significant decline in LGALS3B in association with decline in IL6 discovered for the first 
time in a bariatric model. 
HSP90B1 is an essential immune chaperone to regulate both innate and adaptive im-
munity and has previously been shown to be increased in a zebrafish model of hepatic 
steatosis induced by high-fat and high-cholesterol diet [36]. HSP90B1 gene expression was 
reduced in the hippocampus of a murine model of type 2 diabetes [37]. This protein also 
increases the protective heat shock response by suppressing inflammatory signalling 
pathways in several diseases [38], and it was previously shown that HSP90B1 can increase 
the IL6 secretion in treated N9 microglial cell line [39], which is in accordance with our 
findings. 
Another interesting correlation was between reduction in IL6 and fold change in 
ACE. The role and importance of ACE inhibitors in cardiovascular disease related to obe-
sity and diabetes is well known [40]. ACE inhibitors are effective not only as blood pres-
sure-lowering agents, but also as modulators of metabolic abnormalities. Indeed, experi-
mental evidence indicates that in animal models of insulin resistance, ACE inhibitors ame-
liorate the insulin resistance [40]. 
Lower circulating SHBG levels are associated with insulin resistance [41,42] and it is 
well documented that SHBG levels increase after bariatric surgery [43]. As would be ex-
pected, we found an inverse correlation between change in SHBG (increase) and change 
in CRP (decrease) at 12 months post-surgery. 
The other correlations we found between inflammatory markers (TNFα and CRP) 
with plasma proteins are interesting. However, we consider them as exploratory findings, 
as we did not find statistical differences in those inflammatory markers comparing base-
line and 6 or 12 months post-surgery results. However, it is important to highlight that 
the proteins correlated are involved in process as immunity/pro-inflammatory activity 
[44] and neurocognitive functions [45]. This raises the necessity of further studies in this 
area to validate and confirm our findings. 
Our study contributes and helps to give new direction to the study of proteins with 
possible clinical relevance to the reduction seen in chronic inflammation post-bariatric 
surgery. It has early implications for the development of strategies to reduce low-grade 
inflammation and cognitive impairments in obesity. 
5. Conclusions 
Using SWATH-MS, we identified several proteins that are involved in the inflamma-
tory response that declines in patients who achieve remission of T2DM after metabolic 
bariatric surgery in tandem with changes in IL6, TNFα and/or CRP. Despite a limited 
sample size, we identified key proteins involved in remission from T2DM after MBS. Rep-
lication of these results is now needed together with future studies to understand the 
mechanisms whereby MBS can improve low-grade inflammation. 
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